Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 6/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.46 |
| ▸ | DPP4 | P27487 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 2/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2679602 | 1.00 | SLC1A3 (0.50) | SLC1A3SLC1A2SLC1A1EPHX1DPP4 | |
| SCHEMBL6978063 | 1.00 | SLC1A3 (0.50) | SLC1A3SLC1A2SLC1A1EPHX1DPP4 | |
| Hydrochloric Acid SCHEMBL29027938 | 0.98 | SLC1A3 (0.49) | SLC1A3SLC1A2SLC1A1EPHX1DPP4 | |
| Hydrochloric Acid SCHEMBL7589303 | 0.98 | SLC1A3 (0.49) | SLC1A3SLC1A2SLC1A1EPHX1DPP4 | |
| SCHEMBL26126016 | 0.93 | SLC1A2 (0.48) | SLC1A3SLC1A2SLC1A1EPHX1DPP4 | |
| SCHEMBL24411126 | 0.88 | SLC1A2 (0.45) | SLC1A3SLC1A2SLC1A1GRM2 | |
| SCHEMBL22143593 | 0.88 | SLC1A2 (0.45) | SLC1A3SLC1A2SLC1A1GRM2 | |
| Hydrochloric Acid SCHEMBL22125733 | 0.86 | SLC1A2 (0.44) | SLC1A3SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL22125734 | 0.86 | SLC1A2 (0.44) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL24520309 | 0.82 | SLC1A3 (0.50) | SLC1A3SLC1A2SLC1A1EPHX1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118619931-A | Aryl or heteroaryl derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-09-10 | — | — | CN | disclosed |
| CN-118317962-A | Imidazopyridazine IL-17 inhibitor compounds | 詹森药业有限公司 | 2024-07-09 | — | — | CN | disclosed |
| EP-4201951-B1 | METHOD FOR PEPTIDE SYNTHESIS | BACHEM HOLDING AG (CH) | 2023-11-22 | — | — | EP | disclosed |
| WO-2023117904-A1 | METHOD FOR PEPTIDE SYNTHESIS | BACHEM HOLDING AG (CH) | 2023-06-29 | — | — | WO | disclosed |
| EP-4201951-A1 | METHOD FOR PEPTIDE SYNTHESIS | Bachem Holding AG (CH) | 2023-06-28 | — | — | EP | disclosed |
| WO-2022129630-A1 | G PROTEIN PEPTIDOMIMETICS | VRIJE UNIVERSITEIT BRUSSEL (BE) | 2022-06-23 | — | — | WO | disclosed |
| US-9737622-B2 | Compounds modulators of VEGF activity and uses thereof | ADVANCED ACCELERATOR APPLICATIONS S.A. (FR) | 2017-08-22 | — | — | US | disclosed |
| US-20140341814-A1 | COMPOUNDS MODULATORS OF VEGF ACTIVITY AND USES THEREOF | ADVANCED ACCELERATOR APPLICATIONS S.A. | 2014-11-20 | — | — | US | disclosed |
| US-8741850-B2 | Compounds modulators of VEGF activity and uses thereof | ADVANCED ACCELERATOR APPLICATIONS S.A. (FR) | 2014-06-03 | — | — | US | disclosed |
| US-20120114565-A1 | COMPOUNDS MODULATORS OF VEGF ACTIVITY AND USES THEREOF | ADVANCED ACCELERATOR APPLICATIONS S.A. (FR) | 2012-05-10 | — | — | US | disclosed |
| US-20050004351-A1 | Therapeutic and diagnostic domain 1 beta2GP1 polypeptides and methods of using same | MARQUIS DAVID M (US) | 2005-01-06 | — | — | US | disclosed |
| US-20040009904-A1 | APL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies | VICTORIA EDWARD JESS (US) | 2004-01-15 | — | — | US | disclosed |
| US-6410775-B1 | HYDROPHILIC COUPLING | LA JOLLA PHARMACEUTICAL COMPANY | 2002-06-25 | — | — | US | disclosed |
| EP-1092027-A1 | THERAPEUTIC AND DIAGNOSTIC DOMAIN 1 BETA 2 GP1 POLYPEPTIDES AND METHODS OF USING SAME | LA JOLLA PHARMACEUTICAL COMPANY (CA) | 2001-04-18 | — | — | EP | disclosed |
| WO-1999064595-A9 | THERAPEUTIC AND DIAGNOSTIC DOMAIN 1 β2GPI POLYPEPTIDES AND METHODS OF USING SAME | JOLLA PHARMA (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-1999064595-A1 | THERAPEUTIC AND DIAGNOSTIC DOMAIN 1 β2GPI POLYPEPTIDES AND METHODS OF USING SAME | LA JOLLA PHARMACEUTICAL COMPANY (US) | 1999-12-16 | — | — | WO | disclosed |
| EP-0954531-A1 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | Lajolla Pharmaceutical Company (US) | 1999-11-10 | — | — | EP | disclosed |
| EP-0954531-A4 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | LAJOLLA PHARMACEUTICAL COMPANY (US) | 1999-08-31 | — | — | EP | disclosed |
| WO-1997046251-A9 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | — | 1998-06-04 | — | — | WO | disclosed |
| WO-1997046251-A1 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | LAJOLLA PHARMACEUTICAL COMPANY (US) | 1997-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009904-A1 | APL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies | CD4, VSIG8, PTMS | SLC1A3 1310/4885SLC1A2 2441/4885SLC1A1 2023/4885 |
| US-20050004351-A1 | Therapeutic and diagnostic domain 1 beta2GP1 polypeptides and methods of using same | PLTP, PA2G4, PAG1 | SLC1A3 4090/4885SLC1A2 3891/4885SLC1A1 4166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.